Non Small Cell Lung CancerSP vs MP robotNCT07099105
Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer
An observational study of Non Small Cell Lung Cancer, run by Korea University Guro Hospital at 1 site in South Korea.
Trial summary
The goal of this observational study is compared the perioperative outcomes of robotic lobectomy using the SP system via the subcostal approach with those of multi-port robotic lobectomy using the Xi system via the intercostal approach. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer
- How many people
- 339 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jan 2017to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients aged > 18 years who underwent robotic lobectomy for non-small cell lung cancer at the Korea University Guro Hospital between January 2017 and December 2024. Patients were categorized into the SP and MP groups based on the surgical approach employed.
Who may be able to join
- patients aged > 18 years who underwent RATS lobectomy for NSCLC at the Korea University Guro Hospital between January 2017 and December 2024
Who cannot join
- patients who underwent Viedo-assisted thoracic surgery lobectomy
- patients who underwent robotic lobectomy with other combined surgery
- patients who received neoadjuvant therapy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer: A Single-centre Retrospective Propensity Matched Study
The goal of this observational study is compared the perioperative outcomes of robotic lobectomy using the SP system via the subcostal approach with those of multi-port robotic lobectomy using the Xi system via the intercostal approach.
- Conditions
- Non Small Cell Lung Cancer
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SP group | Patients with non-small cell lung cancer who underwent single-port robotic lobectomy. All procedures were performed using the SP system via the subcostal approach. | |
| MP | Patients with non-small cell lung cancer who underwent multi-port robotic lobectomy. All procedures were performed using the Xi system via the intercostal approach. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain
Postoperative pain using visual analog scale (minimum =0, maximum=10), A lower value reflects a lesser degree of pain perception (lower scores mean a better outcome)
Measured: Postoperatively day 0,1,2,3
Secondary outcomes (1)
chest tube duration
Chest tube duration refers to the number of days a thoracic drain remains in situ following pulmonary surgery. The duration is measured in days (minimum: 1, maximum: no defined). Lower scores indicate a better outcome.
Measured: Perioperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study start1 Jan 2017
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 339 participants (actual)
Sponsor and investigators
- Lead sponsor
- Korea University Guro Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hyun Koo Kim, Korea University Guro Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07099105
- Sponsor's protocol ID
- 2025GR0224
- Acronym
- SP vs MP robot
- Status last verified
- Jul 2025
- First submitted
- 23 Jul 2025
- Last updated
- 1 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Lee JH, Park TH, Kim HK. Robotic thoracic surgery using the single-port robotic system: Initial experience with more than 100 cases. J Thorac Cardiovasc Surg. 2024 Dec;168(6):1513-1522.e2. doi: 10.1016/j.jtcvs.2024.03.005. Epub 2024 Apr 28.
PubMed 38678475
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer: A Single-centre Retrospective Propensity Matched Study
- ClinicalTrials.gov ID
- NCT07099105
- Acronym / sponsor ID
- SP vs MP robot / 2025GR0224
- Conditions
- Non Small Cell Lung Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 339 participants (actual)
- Lead sponsor
- Korea University Guro HospitalUniversity, hospital or other
- Study start
- 1 Jan 2017 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 1 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is compared the perioperative outcomes of robotic lobectomy using the SP system via the subcostal approach with those of multi-port robotic lobectomy using the Xi system via the intercostal approach.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SP group | – | –Patients with non-small cell lung cancer who underwent single-port robotic lobectomy. All procedures were performed using the SP system via the subcostal approach. |
| MP | – | –Patients with non-small cell lung cancer who underwent multi-port robotic lobectomy. All procedures were performed using the Xi system via the intercostal approach. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients aged > 18 years who underwent robotic lobectomy for non-small cell lung cancer at the Korea University Guro Hospital between January 2017 and December 2024. Patients were categorized into the SP and MP groups based on the surgical approach employed.
Key inclusion criteria (1 listed)
- patients aged > 18 years who underwent RATS lobectomy for NSCLC at the Korea University Guro Hospital between January 2017 and December 2024
Key exclusion criteria (3 listed)
- patients who underwent Viedo-assisted thoracic surgery lobectomy
- patients who underwent robotic lobectomy with other combined surgery
- patients who received neoadjuvant therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Postoperative pain
Time frame: Postoperatively day 0,1,2,3
Postoperative pain using visual analog scale (minimum =0, maximum=10), A lower value reflects a lesser degree of pain perception (lower scores mean a better outcome)
1 secondary outcome
chest tube duration
Time frame: Perioperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2025.
- Background: PubMed 38678475Lee JH, Park TH, Kim HK. Robotic thoracic surgery using the single-port robotic system: Initial experience with more than 100 cases. J Thorac Cardiovasc Surg. 2024 Dec;168(6):1513-1522.e2. doi: 10.1016/j.jtcvs.2024.03.005. Epub 2024 Apr 28.
- Individual participant dataSharing planned: Yes
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non Small Cell Lung Cancer, run by Korea University Guro Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain (time frame: Postoperatively day 0,1,2,3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07099105, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2025; AzTrials last refreshed its copy on 6 Nov 2026.